See more : SMN Corporation (6185.T) Income Statement Analysis – Financial Results
Complete financial analysis of HEXO Corp. (HEXO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HEXO Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Star CM Holdings Limited (6698.HK) Income Statement Analysis – Financial Results
- China Infrastructure & Logistics Group Ltd. (1719.HK) Income Statement Analysis – Financial Results
- Rover Metals Corp. (ROVR.V) Income Statement Analysis – Financial Results
- Equasens Société anonyme (EQS.PA) Income Statement Analysis – Financial Results
- Pure Energy Minerals Limited (PE.V) Income Statement Analysis – Financial Results
HEXO Corp. (HEXO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hexocorp.com
About HEXO Corp.
HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. HEXO Corp. has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 191.10M | 123.77M | 80.78M | 47.54M | 4.93M | 4.10M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 266.78M | 74.97M | 138.76M | 20.62M | -1.47M | -2.35M | 0.00 | 0.00 | 0.00 |
Gross Profit | -75.67M | 48.80M | -57.98M | 26.93M | 6.40M | 6.45M | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | -39.60% | 39.43% | -71.77% | 56.64% | 129.72% | 157.39% | 0.00% | 0.00% | 0.00% |
Research & Development | 3.22M | 3.84M | 4.64M | 2.82M | 0.00 | 86.38K | 0.00 | 0.00 | 0.00 |
General & Administrative | 99.31M | 69.92M | 78.58M | 73.96M | 14.37M | 4.27M | 0.00 | 29.29K | 29.29K |
Selling & Marketing | 22.93M | 10.35M | 12.47M | 31.19M | 8.34M | 2.99M | 0.00 | 0.00 | 0.00 |
SG&A | 122.24M | 80.27M | 91.06M | 105.15M | 22.71M | 7.25M | 0.00 | 29.29K | 29.29K |
Other Expenses | 28.78M | 8.15M | 322.88M | 3.51M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 154.24M | 92.25M | 418.58M | 111.48M | 24.37M | 7.93M | 0.00 | 29.29K | 29.29K |
Cost & Expenses | 421.01M | 167.22M | 557.34M | 132.10M | 22.90M | 5.58M | 0.00 | 29.29K | 29.29K |
Interest Income | 1.65M | 1.60M | 1.90M | 5.19M | 2.12M | 92.16K | 0.00 | 0.00 | 0.00 |
Interest Expense | 20.07M | 32.12M | 10.04M | 469.00K | 1.53M | 522.62K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 810.10M | 16.73M | 68.25M | 5.85M | 1.66M | 591.65K | 22.82K | 0.00 | 0.00 |
EBITDA | -257.63M | -26.73M | -476.55M | -78.70M | -14.19M | -1.75M | 0.00 | -29.29K | -29.29K |
EBITDA Ratio | -134.81% | -21.59% | -589.91% | -165.55% | -287.60% | -42.73% | 0.00% | 0.00% | 0.00% |
Operating Income | -1.07B | -43.45M | -476.55M | -84.56M | -17.97M | -1.48M | 0.00 | -29.29K | -29.29K |
Operating Income Ratio | -558.72% | -35.11% | -589.91% | -177.86% | -364.14% | -36.21% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -691.53M | -71.71M | -75.96M | -847.00K | -5.38M | -10.93M | 0.00 | 0.00 | 0.00 |
Income Before Tax | -1.11B | -115.16M | -552.51M | -85.40M | -23.35M | -12.42M | 0.00 | -29.29K | -29.29K |
Income Before Tax Ratio | -582.11% | -93.04% | -683.94% | -179.64% | -473.25% | -303.10% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -38.81M | -397.00K | -6.02M | -3.84M | 1.53M | 522.62K | 0.00 | 0.00 | 0.00 |
Net Income | -1.07B | -114.76M | -546.49M | -81.56M | -23.35M | -12.42M | 0.00 | -29.29K | -29.29K |
Net Income Ratio | -561.80% | -92.72% | -676.48% | -171.57% | -473.25% | -303.10% | 0.00% | 0.00% | 0.00% |
EPS | -38.68 | -12.62 | -63.43 | -21.47 | -9.75 | -11.88 | 0.00 | -0.92 | 0.00 |
EPS Diluted | -38.68 | -12.62 | -63.43 | -21.47 | -9.75 | -11.88 | 0.00 | -0.92 | 0.00 |
Weighted Avg Shares Out | 27.76M | 9.09M | 8.62M | 3.80M | 2.40M | 1.05M | 31.54M | 31.75K | 6.22M |
Weighted Avg Shares Out (Dil) | 27.76M | 9.09M | 8.62M | 3.80M | 2.40M | 1.05M | 31.54M | 31.75K | 6.22M |
HEXO Corp Announces Share Consolidation
HEXO Corp Announces Repayment of 8.0% Unsecured Convertible Debentures
2 Marijuana Stocks To Watch Heading Into A New Month
Canadian Marijuana Stocks To Buy And Hold Till Next Year?
Molson to end its Truss CBD USA Joint Venture with Hexo
HEXO and Entourage Health Sign Long-Term Supply Agreement
Is SNDL's Acquisition of Zenabis a Good Move for the Company?
Top Canadian Marijuana Stocks To Buy? 2 To Watch Under $2
3 Marijuana Stocks That Could See Big Momentum
HEXO: Solid Quarterly Results, Lower Debt
Source: https://incomestatements.info
Category: Stock Reports